NEW ORLEANS — In this video, David A. Eichenbaum, MD, FASRS, of Retina Vitreous Associates of Florida, highlights data from the phase 3 DAYBREAK trial on the use of Zenkuda for the treatment of wet age-related macular degeneration.
In the DAYBREAK clinical trial, presented at the American Academy of Ophthalmology meeting, researchers assessed Zenkuda (tarcocimab tedromer, Kodiak Sciences) and KSI-501 (tabirafusp alfa tedromer, Kodiak Sciences) vs. Eylea (aflibercept, Regeneron) in patients with wet AMD.
Eichenbaum said 54% of patients who received Zenkuda went out as far as 6 months without